Bernard Nordlinger

Active 1978–2021

Also published as
BERNARD NORDLINGER
79
Papers
28,092
Citations
76
h-index
79
i10-index

Citations

Citations per year for Bernard Nordlinger1980: 1 citations1981: 2 citations1982: 8 citations1983: 3 citations1984: 2 citations1985: 4 citations1986: 3 citations1987: 4 citations1988: 1 citations1989: 8 citations1990: 15 citations1991: 10 citations1992: 22 citations1993: 22 citations1994: 24 citations1995: 37 citations1996: 57 citations1997: 56 citations1998: 51 citations1999: 85 citations2000: 79 citations2001: 74 citations2002: 98 citations2003: 85 citations2004: 76 citations2005: 98 citations2006: 125 citations2007: 172 citations2008: 167 citations2009: 189 citations2010: 237 citations2011: 207 citations2012: 215 citations2013: 230 citations2014: 267 citations2015: 223 citations2016: 183 citations2017: 207 citations2018: 130 citations2019: 732 citations2020: 660 citations2021: 626 citations2022: 431 citations2023: 273 citations2024: 405 citations2025: 144 citations2026: 4 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,605 citing papers, 19.1% of this breakdownChina: 865 citing papers, 10.3% of this breakdownItaly: 612 citing papers, 7.3% of this breakdownUnited Kingdom: 539 citing papers, 6.4% of this breakdownFrance: 536 citing papers, 6.4% of this breakdownGermany: 448 citing papers, 5.4% of this breakdownJapan: 436 citing papers, 5.2% of this breakdownNetherlands: 413 citing papers, 4.9% of this breakdownSpain: 259 citing papers, 3.1% of this breakdownCanada: 229 citing papers, 2.7% of this breakdownBelgium: 226 citing papers, 2.7% of this breakdownSwitzerland: 208 citing papers, 2.5% of this breakdown
0%19.1%Other 24%

Fields

  • Medicine81.3%
  • Biochemistry, Genetics and Molecular Biology13.8%
  • Immunology and Microbiology1.3%
  • Computer Science0.9%
  • Engineering0.5%
  • Physics and Astronomy0.5%
  • Other1.7%

Topics

  • Colorectal Cancer Treatments and Studies10.4%
  • Hepatocellular Carcinoma Treatment and Prognosis9.4%
  • Colorectal Cancer Surgical Treatments7.3%
  • Genetic factors in colorectal cancer4.1%
  • Gastric Cancer Management and Outcomes3.4%
  • Cholangiocarcinoma and Gallbladder Cancer Studies2.9%
  • Other62.5%

Coauthors

All papers

Open in search
  1. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Authors: , , , , , , - Annals of Oncology 2013 cited by 1,421

  2. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , - The Lancet Oncology 2013 cited by 1,316

  3. Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial

    Authors: , , , , , , , , , , , , , - JNCI Journal of the National Cancer Institute 2017 cited by 678

  4. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Karin Jordan, Andrey Meshcheryakov, Demetris Papamichail, Per Pfeiffer, Ioannis Souglakos, Serdar Turhal, Andrés Cervantes - Annals of Oncology 2012 cited by 1,534

  5. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

    Authors: , , , , , , , , , , , , , , , , , , - The Lancet 2008 cited by 1,945

  6. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Authors: , , , - Annals of Oncology 2014 cited by 1,193

  7. Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial

    Authors: , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2009 cited by 1,156

  8. Colorectal cancer

    Authors: , , , , , , - The Lancet 2010 cited by 1,355

  9. Surgical resection of colorectal carcinoma metastases to the liver: A prognostic scoring system to improve case selection, based on 1568 patients

    Authors: , , , , , , - Cancer 1996 cited by 1,670

  10. Neoadjuvant Chemotherapy Compared With Surgery Alone for Locally Advanced Cancer of the Stomach and Cardia: European Organisation for Research and Treatment of Cancer Randomized Trial 40954

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2010 cited by 714

  11. Multicenter Randomized Trial of Adjuvant Fluorouracil and Folinic Acid Compared With Surgery Alone After Resection of Colorectal Liver Metastases: FFCD ACHBTH AURC 9002 Trial

    Authors: , , , , , , , , , , , , - Journal of Clinical Oncology 2006 cited by 578

  12. Deep Learning and Radiomics predict complete response after neo-adjuvant chemoradiation for locally advanced rectal cancer

    Authors: , , , , , , , , , , - Scientific Reports 2018 cited by 229

  13. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment

    Authors: , , - Annals of Oncology 2010 cited by 481

  14. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004)

    Authors: , , , , , , , , , , , , - Annals of Oncology 2012 cited by 437

  15. Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 cited by 97

  16. Impaired Mobility, ASA Status and Administration of Tramadol are Risk Factors for Postoperative Delirium in Patients Aged 75 Years or More After Major Abdominal Surgery

    Authors: , , , , , , , - Annals of Surgery 2010 cited by 237

  17. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases

    Authors: , , , , , , , - European Journal of Cancer 2006 cited by 594

  18. Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2009 cited by 468

  19. Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon Cancer

    Authors: , , , , , , , , , , , , - JNCI Journal of the National Cancer Institute 2012 cited by 280

  20. Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983

    Authors: , , , , , , , , , - European Journal of Cancer 2014 cited by 222

  21. Influence of Preoperative Chemotherapy on the Risk of Major Hepatectomy for Colorectal Liver Metastases

    Authors: , , , , , , , - Annals of Surgery 2005 cited by 720

  22. Complete Response of Colorectal Liver Metastases After Chemotherapy: Does It Mean Cure?

    Authors: , , , , , , , , - Journal of Clinical Oncology 2006 cited by 602

  23. Accurate Measurement of Liver, Kidney, and Spleen Volume and Mass by Computerized Axial Tomography

    Authors: , , , , , - Annals of Internal Medicine 1979 cited by 465

  24. Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up

    Authors: , , , , - Annals of Oncology 2010 cited by 339